UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Purchases 911,461 Shares of Johnson & Johnson $JNJ

Key Points

• UBS Asset Management increased its stake in Johnson & Johnson by 5.9% during the first quarter, holding over 16 million shares valued at approximately $2.71 billion.
• Johnson & Johnson reported earnings of $2.77 EPS for the last quarter, surpassing analysts' expectations and showing a 5.8% revenue increase year-over-year.
• The company announced a quarterly dividend of $1.30 per share, reflecting an annualized dividend of $5.20 and a yield of 2.9%.

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 5.9% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 16,354,767 shares of the company's stock after purchasing an additional 911,461 shares during the period. Johnson & Johnson comprises approximately 0.7% of UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC's portfolio, making the stock its 19th biggest holding. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned about 0.68% of Johnson & Johnson worth $2,712,275,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. Highline Wealth Partners LLC raised its stake in shares of Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after acquiring an additional 86 shares during the last quarter. Stone House Investment Management LLC purchased a new position in Johnson & Johnson during the 1st quarter valued at about $47,000. 1248 Management LLC bought a new position in Johnson & Johnson during the 1st quarter valued at approximately $48,000. von Borstel & Associates Inc. purchased a new stake in Johnson & Johnson in the 1st quarter worth approximately $49,000. Finally, Harvest Fund Management Co. Ltd bought a new stake in shares of Johnson & Johnson in the 1st quarter worth approximately $52,000. Hedge funds and other institutional investors own 69.55% of the company's stock.

Insider Buying and Selling

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares of the company's stock, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.16% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on JNJ. Guggenheim restated a "neutral" rating and set a $167.00 target price (up previously from $164.00) on shares of Johnson & Johnson in a report on Thursday, July 17th. Morgan Stanley upped their price objective on shares of Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a report on Thursday, July 17th. Bank of America lifted their target price on shares of Johnson & Johnson from $161.00 to $175.00 and gave the company a "neutral" rating in a research note on Thursday, July 17th. UBS Group increased their price target on shares of Johnson & Johnson from $180.00 to $190.00 and gave the stock a "buy" rating in a research note on Thursday, July 17th. Finally, Royal Bank Of Canada raised their price objective on shares of Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a report on Thursday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $176.29.

Johnson & Johnson Stock Up 1.5%

Shares of Johnson & Johnson stock traded up $2.61 during trading on Thursday, hitting $178.40. The company's stock had a trading volume of 5,790,576 shares, compared to its average volume of 8,919,251. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $181.16. The company has a market capitalization of $429.65 billion, a PE ratio of 19.08, a P/E/G ratio of 2.25 and a beta of 0.40. The company has a fifty day simple moving average of $169.91 and a two-hundred day simple moving average of $161.12. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $23.74 billion for the quarter, compared to analysts' expectations of $22.85 billion. During the same quarter in the prior year, the company earned $2.82 earnings per share. The business's revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were paid a dividend of $1.30 per share. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 2.9%. Johnson & Johnson's payout ratio is presently 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.